NextCure (NXTC)
(Delayed Data from NSDQ)
$1.60 USD
-0.03 (-1.84%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $1.64 +0.04 (2.50%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NXTC 1.60 -0.03(-1.84%)
Will NXTC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NXTC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NXTC
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
NXTC: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade
Other News for NXTC
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NextCure (NXTC) Gets a Buy from Piper Sandler
Buy Rating Affirmed on NextCure’s NC410 Promising Clinical Outcomes in MSS-CRC and Ovarian Cancer
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
NextCure presents Phase 1b data on NC410 and pembrolizumab combo at ASCO